TIDMPOLX

RNS Number : 5145Z

Polarean Imaging PLC

13 January 2020

13 January 2020

Polarean Imaging Plc

("Polarean" or the "Company")

Holding(s) in Company

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary magnetic resonance imaging (MRI) drug-device combination, received notification on 10 January 2020 that Tyndall Investment Management now holds 4,917,016 ordinary shares of GBP0.00037 in Polarean, which represents 4.3% of the Company's issued share capital, with voting rights.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

 
 Polarean Imaging plc                             www.polarean.com / www.polarean-ir.com 
 Richard Hullihen, Chief Executive Officer                               Via Walbrook PR 
 Richard Morgan, Chairman 
 
 SP Angel Corporate Finance LLP                                 Tel: +44 (0)20 3470 0470 
 David Hignell, Soltan Tagiev (Corporate 
  Finance) 
  Vadim Alexandre / Rob Rees (Corporate Broking) 
 
 Walbrook PR                         Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com 
 Paul McManus / Anna Dunphy                       Mob: +44 (0)7980 541 893 / +44 (0)7879 
                                                                                 741 001 
 
 

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate and less harmful to the patient than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

The Group also develops and manufactures high performance MRI radiofrequency (RF) coils which are a required component for imaging (129) Xe in the MRI system. The development of these coils by the Group facilitates the adoption of the Xenon technology by providing application-specific RF coils which optimise the imaging of (129) Xe in MRI equipment for use as a medical diagnostic as well as a method of monitoring the efficacy of therapeutic intervention.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

HOLUUSBRRWUAAAR

(END) Dow Jones Newswires

January 13, 2020 02:00 ET (07:00 GMT)

Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Sep 2020 a Oct 2020 Haga Click aquí para más Gráficas Polarean Imaging.
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Oct 2019 a Oct 2020 Haga Click aquí para más Gráficas Polarean Imaging.